AUR-AFEA-TTP1-A-1-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.440
- INFLAMMATORY_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.340
- ALLOGRAFT_REJECTION+0.300
- HEDGEHOG_SIGNALING+0.290
- NOTCH_SIGNALING+0.230
- MITOTIC_SPINDLE+0.180
- IL2_STAT5_SIGNALING+0.150
- WNT_BETA_CATENIN_SIGNALING+0.140
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.590
- MYC_TARGETS_V1-0.510
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.440
- FATTY_ACID_METABOLISM-0.420
- PROTEIN_SECRETION-0.420
- MTORC1_SIGNALING-0.410
- BILE_ACID_METABOLISM-0.400
- ESTROGEN_RESPONSE_LATE-0.400
- ADIPOGENESIS-0.370
- GLYCOLYSIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313132 | — | D | 0.892 |
| 2 | SRR12696760 | — | — | 0.871 |
| 3 | SRR5088847 | — | — | 0.868 |
| 4 | TCGA-A7-A26F-01B-04R-A22O-07 | — | D | 0.861 |
| 5 | TCGA-E9-A2JT-01A-22R-A18M-07 | — | D | 0.859 |
| 6 | GSM5359433 | — | — | 0.858 |
| 7 | X0e8b5ba7.3bee.4627.a8b6.f94263f78e3e | — | cohortMD2 | 0.856 |
| 8 | s0122308 | — | — | 0.851 |
| 9 | 20110029.TNBC | — | D | 0.842 |
| 10 | TCGA-AC-A3OD-01B-06R-A22O-07 | — | D | 0.838 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.140 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.100 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.050 | Inavolisib | — uncovered |